United Therapeutics Corporation

395 articles about United Therapeutics Corporation

• United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020

  10/21/2020

  United Therapeutics Corporation announced that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020.

• United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020

  10/15/2020

  United Therapeutics Corporation announced it will present clinical trial data on Tyvaso® Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease at CHEST 2020, the annual meeting of the American College of Chest Physicians, which will be held on October 18-21.

• United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/16/2020

  United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors

  9/11/2020

  United Therapeutics Corporation announced the appointment of Linda Maxwell, M.D. to its Board of Directors as an independent director, effective as of September 10, 2020.

• United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease

  8/17/2020

  United Therapeutics Corporation announced that the U.S. Food and Drug Administration accepted for review the supplemental New Drug Application for Tyvaso® Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease.

• United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference

  8/5/2020

  United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Wedbush PacGrow Healthcare Virtual Conference.

• United Therapeutics Corporation Reports Second Quarter 2020 Financial Results

  7/29/2020

  United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2020.

• United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia

  7/23/2020

  United Therapeutics Corporation announced the United States Patent and Trademark Office issued a new patent on July 21, 2020, relating to Tyvaso® Inhalation Solution. The new patent, U.S. Patent No.

• United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020

  7/22/2020

  United Therapeutics Corporation announced that it will report its second quarter 2020 financial results before the market opens on Wednesday, July 29, 2020.

• United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session

  6/17/2020

  United Therapeutics Corporation announced that key data from the INCREASE study of Tyvaso® Inhalation Solution in patients suffering from World Health Organization Group 3 pulmonary hypertension associated with interstitial lung disease will be presented at a Breaking News Session hosted by the American Thoracic Society on June 24, 2020.

• United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

  6/5/2020

  United Therapeutics Corporation announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. for infringement of the following patents relating to United Therapeutics' product Tyvaso® Inhalation Solution: U.S. Patent Nos. 9,604,901 and 9,593,066, both of which expire in December 2028.

• United Therapeutics Corporation to Present at the Jefferies 2020 Virtual Health Care Conference

  5/26/2020

  United Therapeutics Corporation announced that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Health Care Conference.

• United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020

  5/6/2020

  United Therapeutics Corporation announced that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the BofA Securities Virtual Health Care Conference 2020.

• United Therapeutics Corporation Reports First Quarter 2020 Financial Results

  4/29/2020

  United Therapeutics Corporation announced its financial results for the quarter ended March 31, 2020.

• United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

  4/23/2020

  - Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences - Separately, total PAH-related patient healthcare costs are 67% higher for selexipag in article published in Drugs - Real World Outcomes   [23-April-2020]   SILVER SPRING, Md.

• 

  FDA Action Alert: Sanofi, Neurocrine, Correvio and United

  4/20/2020

  Here’s a look at what’s on the U.S. Food and Drug Administration's schedule for the next two weeks.

• United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

  2/26/2020

  United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2019. Full year net revenue decreased 11% to $1,449 million, largely due to the launch of generic versions of Adcirca® in late 2018. Full year net revenue excluding Adcirca increased 3% in 2019 as compared to 2018.

• United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

  2/24/2020

  United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to the Unity Subcutaneous Delivery System for Remodulin® (treprostinil) Injection

• United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints

  2/24/2020

  United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization (WHO)

• United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020

  2/19/2020

  United Therapeutics Corporation announced that it will report its fourth quarter and full year 2019 financial results before the market opens on Wednesday, February 26, 2020.